The Latest on the Coronavirus Outbreak
Tracking COVID-19

Tracking COVID-19

Unsung Heroes

Unsung Heroes

Honoring Our Graduates

Honoring our Graduates

MAP: ArkLaTex school reopening plans

MAP: ArkLaTex school reopening plans

Tracking COVID-19 in the ArkLaTex

Tracking COVID-19 in the ArkLaTex

Unsung Heroes

Unsung Heroes

Honoring our Graduates

Honoring our Graduates

MAP: ArkLaTex school reopening plans

MAP: ArkLaTex school reopening plans

Texas DSHS distributing more cases of antiviral drug remdesivir in Texarkana

Texarkana

AUSTIN (KTAL/KMSS) — Governor Greg Abbott announced Saturday that the Texas Department of State Health Services is distributing a case of the antiviral drug remdesivir to Christus St. Michael Health System in Texarkana.

According to the Governor’s office, the case has been provided to DSHS through the U.S. Department of Health and Human Services. It is the sixth round of distribution from the federal government. At 448 cases, this is the largest distribution and is enough to treat approximately 1,792 patients. This brings the state total to 1,425 cases distributed since May 12.

“As Texas faces an increase in COVID-19 cases and hospitalizations, we remain committed to providing healthcare professionals with the resources they need to respond to this surge and support COVID-19 patients,” said Governor Abbott.

“The State of Texas is grateful to the U.S. Department of Health and Human Services for their continued assistance to equip Texas hospitals with Remdesivir. As we continue to combat the virus, Texas remains committed to keeping our communities healthy and safe.”

Remdesivir has shown promise in early trials in speeding up the recovery time among hospitalized COVID-19 patients. Using a five-day average of hospitalization data, DSHS used county weighting of the number of COVID positive patients in hospitals to determine the number of remdesivir cases per county. Children’s hospitals are eligible this round due to the powder formulation of the medication.

Medical staff at each hospital will determine how the drug will be used, though it must be prescribed in accordance with the Food and Drug Administration’s Emergency Use Authorization, allowing for the treatment of suspected or confirmed COVID-19 in adults and children hospitalized with severe disease, such as those in intensive care.

Preliminary results from a clinical trial showed the average recovery time among patients who received remdesivir was 11 days versus 15 days with a placebo. The supply is part of a donation from drug maker Gilead.

Stay up to date with the latest news and weather by downloading the Arklatexhomepage News App from the App Store or Google Play.

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

 

More Check This Out
Loving Living Local 600x600

Don't Miss